The results show that people with HIV with chronic comorbidities and an unsuppressed HIV viral load could be at greater risk of developing severe COV1
A trial carried out entirely in Catalonia has shown that therapy with dolutegravir plus lamivudine has an efficacy similar to that of triple therapy.1
HIPRA (Amer, Girona) is looking for volunteers aged between 18 and 39 who have not received any COVID-19 vaccine and who have not had the infection,1
5 June 2021 marks the 40th anniversary of the first description of cases of what would later be known as Acquired Immunodeficiency Syndrome (AIDS). T1
This Tuesday, a new edition of the UB-Gilead HIV-Viral Hepatitis Chair was presented. The Chair was created by the University of Barcelona, in collab1
The COVID-19 pandemic has raised concerns about the risk of people with different kinds of immunosuppression developing more serious forms of the inf1
Despite the enormous progress made in the treatment of HIV, the spread of HIV remains uncontrolled around the world. The number of new infections has1
